Skip to main content

Cord Blood Establishing a National Hematopoietic Stem Cell Bank Program (2005) / Chapter Skim
Currently Skimming:

Index
Pages 301-314

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 301...
... , 25, 79, 96­97, 102 Accreditation recommendations, 99­102 Standards Committee, 97 accrediting organization, 102 American Red Cross (ARC) , 24, 87, 199 collection site, 100 Cord Blood Program, 80 cord blood banks, 100­101 American Society for Histocompatibility transplant facility, 101 and Immunogenetics (ASHI)
Read the entire page →
From page 302...
... , 45, 209­217 Clinical testing and quality control, 248­ failures treatable by transplantation of 249 cord blood, 63 Clinical use of cord blood in treating Bone Marrow Donors Worldwide (BMDW) , inherited diseases, examples of 122­123, 258 effective, 62 Bone marrow transplantation (BMT)
Read the entire page →
From page 303...
... , 191 selecting, 138 Criteria that offer both private and public, 161 for data sharing, establishing, 18, 138 in the United States, list of, 24n to determine which units are for Cord Blood Center. See National Cord transplant, 172­175 Blood Coordinating Center to determine which units are suitable for Cord blood collection, establishing uniform banking, 168­171 standards for, 8, 83 Crohn's disease, 68 Cord Blood Coordinating Center.
Read the entire page →
From page 304...
... infection, 59, 169, 112 273­274, 279 permanent unavailability of, 23 protecting confidentiality and privacy of, 116 D transient unavailability of, 23 unavailability of, 23 Danielle Martinez Act, 95 understanding the limitation of their Data sharing, establishing criteria for, 18, rights, 9, 118 138 Duchene muscular dystrophy, 214 Databases, outcomes, 16­17, 136 Duke University, 62, 87 De-identification, 118 Carolinas Cord Blood Bank, 48, 80 Detroit donors, 87 Deviations, 101 Differentiated myeloid cells, 215 E Dimethyl sulfoxide (DMSO) , a cryopreservative agent, 81, 85, EMBASE, 143 205 Engraftment Discard rate, 233 lack of, 213 Disclosure, of information regarding long-term, 62 screening and other risks, 112­114 Epitopes, serologic, 250 Discount rate, 234 Equity, 235­237 Discrepancies, major, clouding the cord Ethical and legal issues, 19, 106­119 blood field, 214­215 cord blood research, 5, 117­118 Diseases, 256­257.
Read the entire page →
From page 305...
... , 5, 7­8, 11, inventory growth, 17, 137, 198­199 13­14, 26, 80, 102, 132 Hematological chimerism, 68 Hematological malignancies, 60 G Hematopoietic progenitor cell (HPC) , 1­7, 13, 56­57, 59, 63­69, 75, 97, 127, Gastrointestinal disorders, umbilical cord 298 blood in, 68 distribution systems for, 10, 130 Genetic diseases treatable by transplantation donating, 23 of cord blood, 63, 69 ex vivo expansion of cord blood derived bone marrow failures, 63 from, 58­59 immune deficiency diseases, 21, 63 homing receptors, 61 metabolic storage disorders, 21, 63 multipotent, 33 Genetic screening, 184 sources of, 5 Good tissue practice (GTP)
Read the entire page →
From page 306...
... overview, formation of multiple peripheral blood 242­266 cells from multipotent, 34 donor selection, 258­264 Hematopoietic stem cell (HSC) key observations on HLA and transplantation, 5, 33­55 hemotopoietic stem cell biological characteristics of umbilical transplantation, 242­243 cord blood, 33­38 probability of finding an allele match for cord blood transplantation, 38­50 HLA loci, 264­266 Hemoglobinopathies, 169, 298 research, 266 Hepatitis B core antibody (hbcAb)
Read the entire page →
From page 307...
... , 112, Joint Commission for Accreditation of 117, 172 Healthcare Organizations (JCAHO) , 249 Intermediate resolution level, 171, 253­254 Internal audits, 101 International Bone Marrow Transplant K Registry (IBMTR)
Read the entire page →
From page 308...
... See National Cord Blood model, 277 Policy Board McCarthy Cord Blood Bank, 87 National Bone Marrow Donor Registry Medical information, promoting the security (NBMDR) , 24 of, 9, 116­117 National Cord Blood Bank Program.
Read the entire page →
From page 309...
... See also Potential nonhematopoietic differentiation P from bone marrow cells; Potential nonhematopoietic uses for stem cells Panel on Cost-Effectiveness in Medicine and in cord blood Health, 234 determining usefulness of cord blood in, Parameter values for costs, 232­234 216 administrative costs, 234 Nonhematopoietic tissues collection and storage costs, 233­234 in clinical specimens, circulating cells cost of transplantation, 234 contribution to, 212 discard rate, 233 differentiation from HSCs, 210­211 discount rate, 234 mechanism of HSC-derived initial endowment, 234 incorporation in, 213­214
Read the entire page →
From page 310...
... See also National Cord Blood collection of cord blood units, 82­83 Policy Board; National inventory screening maternal donors and cord policy blood, 81­82 regarding who must provide consent, storage, 84­86 cord blood centers needing, 9, 109­ transport of cord blood and cell 110 viability, 83­84 Polymorphic sequences, 246, 250 Proposed structure of a national program, Potential nonhematopoietic differentiation 15 from bone marrow cells, 209­214, Public cord blood banks, 76, 78, 158­159, 263­264 161, 298 after bone marrow transplantation, 209­ Public Cord Blood Tissue Bank, 94­95 210 Pulse duplicator bioreactors, 65 human transplantation data, 211­212 lack of engraftment reported, 213 mechanism of HSC-derived Q incorporation in nonhematopoietic tissue, 213­214 Quality assurance systems, 100 nonhematopoietic differentiation from establishing uniform, 8, 86 Quality of life of patients, 120 HSCs, 210­211 prevalence of "transdifferentiation," 213 Potential nonhematopoietic uses for stem R cells in cord blood, 208­217 abstract, 208­209 Racial and ethnic compositions, 124 determining usefulness of CB in non- of the units in cord blood banks, 86­87, hematopoietic repair, 216 167 differences between stem cells in cord Raw data analysis, 146 blood and bone marrow, 216­217 Receptor contact residues, 246 evidence, 214­215 Recombinant human stem cell factor implications for cell therapy using CB or (rHuSCF) , 61 BM transplantation, 215­216 Recommendations, 19 introduction, 209 applying uniform quality standards to all major discrepancies clouding the field, cord blood banks, 8, 103 214­215 continuing to conduct outcomes research, 11, 127
Read the entire page →
From page 311...
... INDEX 311 cord blood centers needing policies Registries, 298 regarding who must provide consent, cord blood banks as repositories, 266 9, 109­110 international, 258 cord blood donors understanding the optimizing size to find a match, 265­266 limitation of their rights, 9, 118 Registry search algorithms, selection of developing a mechanism to make potential HLA matches by, 263­264 nonclinical units available for Regression analysis, 83 research use, 18­19, 69 Relapse risk, 44 developing an outcomes database for all and graft-versus-leukemia effect, 47 sources of HPCs, 16­17, 136 Related donors, 257 establishing a National Cord Blood Relationships that the IOM committee Coordinating Center, 14­16, 133­ envisions under the governance 134 structure described in its establishing a National Cord Blood recommendations, 135 Policy Board, 14, 132­133 Replicative capacities of cells, 35 establishing a national inventory policy, Research, 19, 56­74, 266 10, 126­127 developing a mechanism to make establishing criteria for data sharing, 18, nonclinical units available for, 18­ 138 19, 69 establishing FDA licensure of cord blood developing research priorities, 69 units, 8, 94 effective clinical use of cord blood in establishing uniform quality assurance treating inherited diseases, 62­63 systems, 8, 86 genetic diseases treatable by establishing uniform standards for cord transplantation of cord blood, 63 blood collection, 8, 83 improving current transplant technology, expanding the current inventory, 11, 56­61 127 registries/cord blood banks as funding banks to promote inventory repositories, 266 growth, 17, 137 umbilical cord blood in regenerative identifying a Cord Blood Accrediting medicine, 64­69 Organization, 8, 80 Research Involving Human Biological obtaining informed consent prior to Materials: Ethical Issues and Policy labor and delivery, 9, 111 Guidance, 115 promoting the security of medical Results. See also Survey results information, 9, 116­117 confirming, 282 providing donors with clear information Rights, of cord blood donors, limiting, 9, about their options, 9, 111 118 providing financial support for infrastructure development, 17­18, 138 S Recommended direction for accreditation, 99­102 San Diego donors, 87 Scientific Advisory Committee for Organ an accrediting organization, 102 collection site, 100 Transplantation, 133 cord blood banks, 100­101 Screening completed prior to storage, 184­ 191 transplant facility, 101 Recommended structure of a national genetic screening, 184 program, 129­139 infectious disease testing, 185­187 other exclusions, 188­191 national oversight, 132­133 structure and governance, 133­139 Screening maternal donors, and cord blood, Regenerative potential, 68 81­82
Read the entire page →
From page 312...
... , international registries and cord blood 191 banks, 258 Summaries related donors, 257 of current research, 64 SouthEastern Organ Procurement of HLA matches, 264­265 Foundation (SEOPF) , 249 of recommendations for establishing a Spinal cord injury, umbilical cord blood in, National Cord Blood Stem Cell Bank 66­67 program, 19 St.
Read the entire page →
From page 313...
... count, 80, 222, 184­191 274, 278­279, 282 self-reported accreditation, 162 Total number of usable units, 123 storage of the units, 204­205 Total units collected, by bank, 165 total units collected, by bank, 165 Toxic liver injury, umbilical cord blood in, tracking units, 177 68 types of banks, 161 Tracking units, 177 units that are not usable for transplant, Transdifferentiation events, 65, 69, 210, 176 214 prevalence of, 213 Transient donor unavailability, 23 T Transient warming events (TWE) , 86 Transit time, 83 T cells, 45, 47, 62 Transplant Amendments Act of 1990, 24 alloreactive, 257 Transplant-related mortality (TRM)
Read the entire page →
From page 314...
... , 169, 190 central nervous system disease, 66 White blood cell (WBC) , 38 gastrointestinal disorders, 68 Wiskott-Aldrich syndrome, clinical use of gene therapy, 69 cord blood in treating, 62 spinal cord injury, 66­67 Women.
Read the entire page →

Key Terms

  • cord blood
  • marrow failure
  • bone marrow


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.